X
AI startup Nucleai has immuno-oncology treatment failures in its sights
https://pharmaphorum.com/news/ai-startup-nucleai-has-immuno-oncology-treatment-failures-in-its-sights/
biomarker
4th Microbiome Movement – Drug Development Europe Summit
Microbiome Movement – Drug Development Europe Summit
Mike Page, Alexion Pharmaceuticals invite to SMi’s Orphan Drugs & Rare Diseases
Mike Page, invite to Orphan Drugs & Rare Diseases
Cancer blood test firm Grail mulls IPO
Grail, the US-based cancer detection startup backed by billionaires Jeff Bezos and Bill Gates is reportedly mulling a launch on the Hong Kong stock exchange.
Keytruda wins another first with approval based on biomarkers
For the first time, FDA approves drug on the basis of biomarkers, rather than location.
Artificial intelligence: the way ahead for pharma
What has been its impact on the pharma and healthcare sectors?